Results 211 to 220 of about 92,971 (266)

Immunophenotyping of Chronic Lymphoid Leukemias

Journal of Clinical Oncology, 2008
The 1983 article entitled “Chronic lymphocytic leukemia and other chronic lymphoid proliferations: surface marker phenotypes and clinical correlations,” which is reprinted in this issue of the Journal of Clinical Oncology, was one of the first reporting the use of monoclonal antibodies to expand the phenotypic characterization of chronic lymphoid ...
openaire   +2 more sources

Chronic lymphoid leukemia

Hématologie, 2013
hma.2013.0854 Auteur(s) : Bruno Cazin b-cazin@chru-lille.fr Service des maladies du sang, CHRU de Lille, Hopital Huriez, Lille Comment traiter une leucemie lymphoide chronique (LLC) ? Avant de repondre a cette question, se pose une question prealable : dois-je traiter ce patient atteint de LLC ?
openaire   +1 more source

Lonidamine in the Treatment of Chronic Lymphoid Leukemia

Oncology, 2009
Blood and/or bone marrow cells from patients with hematological malignancies, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia in blastic phase, acute lymphoid leukemia, acute myeloid leukemia, prolymphocytic leukemia, multiple myeloma and myelofibrosis, were incubated with Lonidamine at different concentrations (50, 100 and 160 μg/ml) for ...
Tura S, Cavo M, GOBBI, MARCO, Franchi P.
openaire   +3 more sources

Monoclonal antibodies in the treatment of lymphoid leukemia

Drugs of Today, 2003
MoAb-based therapies are evolving into the first broad-spectrum class of targeted anti-leukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAb available.
Susan, O'Brien, Francis J, Giles
openaire   +2 more sources

Childhood and Adolescent Lymphoid and Myeloid Leukemia

Hematology, 2004
AbstractRemarkable progress has been made in the past decade in the treatment and in the understanding of the biology of childhood lymphoid and myeloid leukemias. With contemporary improved risk assessment, chemotherapy, hematopoietic stem cell transplantation and supportive care, approximately 80% of children with newly diagnosed acute lymphoblastic ...
Ching-Hon, Pui, Martin, Schrappe, Raul C, Ribeiro, Charlotte M, Niemeyer   +3 more
openaire   +3 more sources

INFECTION AND LYMPHOID LEUKEMIA

Journal of the American Medical Association, 1958
To the Editor:— On Sept. 1, 1956, four children of a family developed diarrhea and vomiting. Three of them recovered after seven days. The fourth sibling continued having diarrhea and anorexia. About 14 days after this illness began, the mother noted that he was pale and that he had some bluish spots on the skin.
openaire   +1 more source

Dynamic Morphology of Human Lymphoid Leukemias

1978
In descriptions of scanning electron micrographs of normal and leukemic white blood cells, little thought has been given to the fact that surface morphology and shape are a function of cell motility and, thus, subject to frequent changes. Consideration of these facts necessitates the combination of scanning electron microscopy (SEM) with ...
G, Haemmerli, H, Felix, P, Sträuli
openaire   +2 more sources

Lymphoid Leukemias

2023
Sarah Elitzur, Shai Izraeli, Dina Ben-Yehuda, Moshe E. Gatt   +3 more
openaire   +1 more source

Acute Lymphoid Leukemia

Pediatric Annals, 1978
J M, Lusher, Y, Ravindranath
openaire   +2 more sources

Induction of apoptosis in lymphoid and myeloid leukemia

Current Oncology Reports, 2006
Defects in the core machinery of the apoptosis pathway contribute to chemoresistance and poor outcomes in patients with acute leukemia. To overcome these defects, novel molecules that target key proteins in the apoptosis pathway are being developed. This review highlights compounds that target the mitochondrial, death receptor, and convergence pathways
openaire   +2 more sources